<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Edaravone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Edaravone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Edaravone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="113223" href="/d/html/113223.html" rel="external">see "Edaravone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50131907"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Radicava;</li>
<li>Radicava ORS;</li>
<li>Radicava ORS Starter Kit</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53910694"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Radicava</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F50080081"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Free Radical Scavenger</li></ul></div>
<div class="block doa drugH1Div" id="F50170471"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a1f0b9b-307c-4dfa-ad3e-6402def7e3f4">Amyotrophic lateral sclerosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amyotrophic lateral sclerosis</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial cycle: 60 mg once daily for 14 days, followed by a 14-day drug-free period.</p>
<p style="text-indent:-2em;margin-left:6em;">Subsequent cycles: 60 mg once daily for 10 days within a 14-day period, followed by a 14-day drug-free period.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial cycle: 105 mg (5 mL) once daily for 14 days, followed by a 14-day drug-free period.</p>
<p style="text-indent:-2em;margin-left:6em;">Subsequent cycles: 105 mg (5 mL) once daily for 10 days within a 14-day period, followed by a 14-day drug-free period.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Switching from IV to oral therapy: </i></b>Patients treated with 60 mg IV may be switched to 105 mg orally at the same dosing frequency; follow food consumption dosing recommendations.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992020"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989300"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F50170472"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F50102579"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for intravenous formulation in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:2em;">Hematologic &amp; oncologic: Bruise (15%)</p>
<p style="text-indent:2em;">Nervous system: Abnormal gait (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (8%), eczema (7%), tinea (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Glycosuria (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (≤6%), hypoxia (≤6%), respiratory failure (≤6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F50076892"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to edaravone or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F50149226"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (eg, redness, wheals, erythema multiforme) and anaphylaxis have been reported. If hypersensitivity occurs, discontinue treatment and monitor.</p>
<p style="text-indent:-2em;margin-left:4em;">• Port infections: Port infections leading to hospitalization may occur, in both early and long-term treatment with edaravone (Witzel 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium bisulfite: May contain sodium bisulfite; use caution in patients with asthma or a sulfite allergy.</p></div>
<div class="block foc drugH1Div" id="F50131908"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Radicava: 30 mg/100 mL (100 mL) [contains sodium bisulfite]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Radicava ORS: 105 mg/5 mL (50 mL) [contains sodium bisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Radicava ORS Starter Kit: 105 mg/5 mL (35 mL) [contains sodium bisulfite]</p></div>
<div class="block geq drugH1Div" id="F50131906"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F50170431"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Radicava Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/100 mL (per mL): $7.48</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Radicava ORS Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">105 mg/5 mL (per mL): $320.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Radicava ORS Starter Kit Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">105 mg/5 mL (per mL): $320.71</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53910695"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Radicava: 30 mg/100 mL (100 mL) [contains sodium bisulfite]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Radicava: 105 mg/5 mL (35 mL, 50 mL) [contains sodium bisulfite]</p></div>
<div class="block adm drugH1Div" id="F50170476"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV use only. Administer as two consecutive 30 mg infusion bags (60 mg total) over 60 minutes (infusion rate: ~1 <b>mg</b>/minute [3.33 <b>mL</b>/minute]). Do not mix edaravone with other medications. Do not use if the oxygen indicator has turned blue or purple before opening. Promptly discontinue with any signs or symptoms consistent with a hypersensitivity reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer orally in the morning on an empty stomach after overnight fasting (8 hours for high-fat meal [800 to 1,000 calories; 50% fat]; 4 hours for a low-fat meal [400 to 500 calories, 25% fat], or 2 hours for caloric supplement [250 calories, eg, protein drink]); do not consume food (except water) for 1 hour after administration. Invert bottle upside down and shake vigorously for ≥30 seconds prior to opening. Administer using the provided calibrated measuring device (5 mL oral syringe); do not use a household teaspoon or tablespoon (overdosage may occur).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrostomy/NG tube:</b> Administer enterally via a silicone, PVC, or polyurethane percutaneous endoscopic gastrostomy or NG tube. Flush tube with at least 30 mL of water before and after administration. Administer on an empty stomach after overnight fasting (8 hours for high-fat meal [800 to 1,000 calories; 50% fat]; 4 hours for a low-fat meal [400 to 500 calories, 25% fat], or 2 hours for caloric supplement [250 calories, eg, protein drink]).</p></div>
<div class="block use drugH1Div" id="F50076891"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Amyotrophic lateral sclerosis:</b> Treatment of amyotrophic lateral sclerosis (ALS)</p></div>
<div class="block cyt drugH1Div" id="F50101827"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F50101824"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block foi drugH1Div" id="F56918831"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">A high-fat meal decreased C<sub>max</sub> and AUC by 82% and 61%, respectively, compared to the fasted state. Management: Must be taken on an empty stomach following fasting schedule.</p></div>
<div class="block pri drugH1Div" id="F50149207"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in some animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F50149224"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if edaravone is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F50170478"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hypersensitivity reactions</p></div>
<div class="block pha drugH1Div" id="F50149236"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The mechanism by which edaravone slows the decline of physical function in patients with ALS is unknown. Edaravone is a free radical and peroxynitrite scavenger that prevents oxidative damage to cell membranes and may contribute to inhibiting the progression of ALS (Nagase 2016).</p></div>
<div class="block phk drugH1Div" id="F50170456"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: C<sub>max</sub> decreased by 82% and AUC decreased by 61% when administered with a high-fat meal compared to fasted conditions; following administration 4 hours after a high-fat meal, C<sub>max</sub> decreased by 44% and AUC decreased by 24%; following administration 2 hours after a low-fat meal, C<sub>max</sub> decreased by 45% and AUC decreased by 21%.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 92% (mainly albumin).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: IV: 63.1 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized to inactive sulfate and glucuronide conjugates; sulfate conjugate formed by sulfotransferases. Glucuronide conjugation involves UGT1A6, UGT1A9, UGT2B7, and UGT2B17 in the liver and kidney.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 57%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~4.5 to 9 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: IV: 1 hour; Oral: 0.5 hours (range: 0.25 to 0.75 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (60% to 80% as glucuronide conjugate; 6% to 8% as sulfate conjugate; ≤1% unchanged).</p></div>
<div class="block phksp drugH1Div" id="F55653983"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Following a single 30 mg IV infusion, mean C<sub>max</sub> and AUC<sub>0-∞</sub> of unchanged edaravone were 1.15- and 1.20-fold greater in subjects with mild impairment (eGFR 60 to 89 mL/minute/1.73 m<sup>2</sup>), and 1.25- and 1.29-fold greater in subjects with moderate impairment (eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>) when compared to subjects with normal renal function, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Following a single 30 mg IV infusion, mean C<sub>max</sub> and AUC<sub>0-∞</sub> of unchanged edaravone were 1.20- and 1.07-fold greater in the subjects with mild impairment (Child-Pugh score 5 or 6), 1.24- and 1.14-fold greater in subjects with moderate impairment (Child-Pugh score 7 to 9), and 1.20- and 1.19-fold greater in the subjects with severe impairment (Child-Pugh score 10 to 14) when compared to subjects with normal hepatic function, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50169047"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Edaracut</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Radicava</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bi cun | Edaravone and sodium chloride | Yi da sheng</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Radicut</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Radicava</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aravon | Carevon | Edaject | Edanox | Edavit | Edavon | Edinova | Edvo | Ezycut | Fraseda</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Edaravone Meiji | Edaravone Pfizer | Edaravone Takata | Edaravone Towa | Radicut | Radicut ors</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Radicut</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Radicut</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Radicut</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aravon</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Radicava</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Xavron</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26191780">
<a name="26191780"></a>Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. <i>Redox Rep</i>. 2016;21(3):104-112. doi: 10.1179/1351000215Y.0000000026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edaravone-drug-information/abstract-text/26191780/pubmed" id="26191780" target="_blank">26191780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Radicava.1">
<a name="Radicava.1"></a>Radicava and Radicava ORS (edaravone) [prescribing information]. Jersey City, NJ: Mitsubishi Tanabe Pharma America Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35006266">
<a name="35006266"></a>Witzel S, Maier A, Steinbach R, et al; German Motor Neuron Disease Network (MND-NET). Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. <i>JAMA Neurol</i>. 2022;79(2):121-130. doi:10.1001/jamaneurol.2021.4893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edaravone-drug-information/abstract-text/35006266/pubmed" id="35006266" target="_blank">35006266</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 113074 Version 73.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
